• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    3/13/24 5:32:47 PM ET
    $APM
    $BGXX
    $CYTH
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $APM alert in real time by email

    Gainers

    • Molina Healthcare (NYSE:MOH) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion.
    • Evoke Pharma (NASDAQ:EVOK) shares rose 18.54% to $0.76. The market value of their outstanding shares is at $6.4 million.
    • Aptorum Gr (NASDAQ:APM) stock rose 11.75% to $4.84. The company's market cap stands at $25.0 million.
    • Galecto (NASDAQ:GLTO) shares moved upwards by 10.49% to $0.83. The company's market cap stands at $22.5 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) stock moved upwards by 9.99% to $1.21. The market value of their outstanding shares is at $17.8 million.
    • Cyclo Therapeutics (NASDAQ:CYTH) shares increased by 9.87% to $1.78. The company's market cap stands at $50.8 million.

    Losers

    • Spruce Biosciences (NASDAQ:SPRB) stock declined by 75.2% to $1.29 during Wednesday's after-market session. The market value of their outstanding shares is at $52.5 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) stock fell 9.1% to $0.59. The market value of their outstanding shares is at $21.0 million.
    • NuCana (NASDAQ:NCNA) stock fell 8.58% to $0.38. The market value of their outstanding shares is at $20.2 million.
    • Regencell Bioscience (NASDAQ:RGC) stock decreased by 7.9% to $5.6. The market value of their outstanding shares is at $72.8 million.
    • Bright Green (NASDAQ:BGXX) shares declined by 7.48% to $0.26. The company's market cap stands at $47.8 million.
    • Lipocine (NASDAQ:LPCN) stock declined by 7.1% to $4.45. The company's market cap stands at $23.6 million. The company's, Q4 earnings came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APM
    $BGXX
    $CYTH
    $EVOK

    CompanyDatePrice TargetRatingAnalyst
    Molina Healthcare Inc
    $MOH
    2/20/2026$141.00Overweight → Equal Weight
    Wells Fargo
    Galecto Inc.
    $GLTO
    2/17/2026$45.00Buy
    UBS
    Galecto Inc.
    $GLTO
    1/7/2026$46.00Outperform
    Leerink Partners
    Spruce Biosciences Inc.
    $SPRB
    12/23/2025$283.00Outperform
    Oppenheimer
    Spruce Biosciences Inc.
    $SPRB
    12/3/2025$160.00Market Perform → Outperform
    Leerink Partners
    Galecto Inc.
    $GLTO
    12/1/2025$32.00Buy
    Guggenheim
    Spruce Biosciences Inc.
    $SPRB
    10/28/2025$254.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Molina Healthcare Inc
    $MOH
    10/24/2025$144.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $APM
    $BGXX
    $CYTH
    $EVOK
    SEC Filings

    View All

    SEC Form 8-K filed by Lipocine Inc.

    8-K - Lipocine Inc. (0001535955) (Filer)

    4/2/26 9:40:13 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Lipocine Inc. (0001535955) (Filer)

    4/2/26 9:35:13 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    3/31/26 4:54:54 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $BGXX
    $CYTH
    $EVOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Patel Mahesh V.

    4 - Lipocine Inc. (0001535955) (Issuer)

    4/2/26 5:05:58 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Grohowski Leo P

    4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)

    4/2/26 4:49:04 PM ET
    $MOH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Lockhart Stephen H

    4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)

    4/2/26 4:48:22 PM ET
    $MOH
    Medical Specialities
    Health Care

    $APM
    $BGXX
    $CYTH
    $EVOK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zoretic Richard C bought $100,128 worth of shares (800 units at $125.16) (SEC Form 4)

    4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)

    2/12/26 8:27:47 PM ET
    $MOH
    Medical Specialities
    Health Care

    Large owner Parkman Healthcare Partners Llc bought $4,585 worth of shares (256 units at $17.91) and sold $4,920 worth of shares (257 units at $19.14) (SEC Form 4)

    4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

    10/15/25 4:32:43 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Parkman Healthcare Partners Llc bought $4,585 worth of shares (256 units at $17.91) and sold $4,920 worth of shares (257 units at $19.14) (SEC Form 4)

    4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

    10/8/25 8:55:08 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $BGXX
    $CYTH
    $EVOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

    NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, March 19, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") today announced financial results for the fourth quarter and year ended December 31, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We are excited to enter 2026 with significant momentum as we continue to advance the development of our P

    3/19/26 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

    SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the full year ended December 31, 2025 and provided a corporate update. "We believe 2025 was a pivotal year for Lipocine as we continue to advance our pipeline and expand our market presence. The progress we've made, especially with our postpartum depression therapeutic, LPCN 1154, demonstrates the strength of our science and our team's c

    3/10/26 8:00:00 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

    NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens" in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, condu

    3/10/26 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $BGXX
    $CYTH
    $EVOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Molina Healthcare downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Molina Healthcare from Overweight to Equal Weight and set a new price target of $141.00

    2/20/26 8:22:16 AM ET
    $MOH
    Medical Specialities
    Health Care

    UBS initiated coverage on Galecto with a new price target

    UBS initiated coverage of Galecto with a rating of Buy and set a new price target of $45.00

    2/17/26 8:59:23 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Galecto with a new price target

    Leerink Partners initiated coverage of Galecto with a rating of Outperform and set a new price target of $46.00

    1/7/26 8:34:02 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $BGXX
    $CYTH
    $EVOK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TESTOSTERONE UNDECANOATE issued to LIPOCINE INC

    Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    3/29/22 4:34:43 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Tentative Approval for TESTOSTERONE UNDECANOATE

    Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Tentative Approval' on 12/08/2020. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    12/20/20 4:30:41 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $BGXX
    $CYTH
    $EVOK
    Financials

    Live finance-specific insights

    View All

    Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

    SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the full year ended December 31, 2025 and provided a corporate update. "We believe 2025 was a pivotal year for Lipocine as we continue to advance our pipeline and expand our market presence. The progress we've made, especially with our postpartum depression therapeutic, LPCN 1154, demonstrates the strength of our science and our team's c

    3/10/26 8:00:00 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Molina Healthcare Announces First Quarter 2026 Earnings Release and Conferences Call Dates and Investor Day Meeting

    Molina Healthcare, Inc. (NYSE:MOH) ("Molina" or the "Company") today announced it will issue its earnings release for the first quarter ending March 31, 2026, after the market closes on Wednesday, April 22, 2026, and will host a conference call and webcast to discuss the earnings release on Thursday, April 23, 2026, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 4352622. A telephonic replay of the conference call will be available through Thursday, April 30, 2026, by dialing (855) 669-9658 and entering the confirmation number, 6456388. A live broadcast of Molina Healthcare's conference call will be available on

    2/26/26 4:15:00 PM ET
    $MOH
    Medical Specialities
    Health Care

    Molina Healthcare Reports Fourth Quarter and Year-End 2025 Financial Results

    Introduces Full Year 2026 Revenue and Earnings Guidance Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today reported fourth quarter 2025 GAAP loss per diluted share of $3.15 and adjusted loss per diluted share of $2.75. The Company also reported full year 2025 GAAP earnings per diluted share of $8.92 and adjusted earnings per diluted share of $11.03. Financial results are summarized below:   Three months ended   Year ended   December 31,   December 31,   2025   2024   2025   2024                 (In millions, except per-share resu

    2/5/26 4:15:00 PM ET
    $MOH
    Medical Specialities
    Health Care

    $APM
    $BGXX
    $CYTH
    $EVOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

    SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

    11/14/24 5:45:17 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

    SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

    11/14/24 4:39:47 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molina Healthcare Inc

    SC 13G/A - MOLINA HEALTHCARE, INC. (0001179929) (Subject)

    11/14/24 1:22:34 PM ET
    $MOH
    Medical Specialities
    Health Care

    $APM
    $BGXX
    $CYTH
    $EVOK
    Leadership Updates

    Live Leadership Updates

    View All

    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate update

    3/9/26 7:05:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

    Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks previously served as Chief Commercial Officer of Applied Therapeutics and was responsible

    3/9/26 7:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance